{"id":"adalimumab-every-week","safety":{"commonSideEffects":[{"rate":"12-20","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"0.1-0.5","effect":"Tuberculosis reactivation"},{"rate":"1-3","effect":"Opportunistic infections"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine involved in autoimmune and inflammatory diseases. By blocking TNF-alpha signaling, it suppresses the inflammatory cascade and reduces disease progression. The weekly dosing regimen represents a modified administration schedule of the established adalimumab molecule.","oneSentence":"Adalimumab is a TNF-alpha inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:59:33.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriasis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT04527380","phase":"PHASE3","title":"A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2021-04-13","conditions":"Juvenile Psoriatic Arthritis, Enthesitis Related Arthritis","enrollment":101},{"nctId":"NCT06045754","phase":"PHASE4","title":"A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease","status":"RECRUITING","sponsor":"Takeda","startDate":"2024-04-18","conditions":"Crohn's Disease","enrollment":100},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07061574","phase":"PHASE1, PHASE2","title":"A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-03-30","conditions":"Type 1 Diabetes, New Onset","enrollment":120},{"nctId":"NCT06996652","phase":"PHASE2","title":"An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-04","conditions":"REM Sleep Behavior Disorder","enrollment":108},{"nctId":"NCT06037811","phase":"PHASE2","title":"Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis","status":"RECRUITING","sponsor":"Tom Appleton","startDate":"2024-04-15","conditions":"Inflammatory Arthritis, Immune-related Adverse Event","enrollment":30},{"nctId":"NCT07423533","phase":"PHASE2","title":"Phase IIb Clinical Study to Assess the Efficacy and Safety of GenSci120 Injection in Patients With Moderately to Severely Active RA Who Have an Inadequate Response to at Least One DMARD","status":"NOT_YET_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2026-02","conditions":"Rheumatoid Arthritis","enrollment":450},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT06941376","phase":"PHASE2","title":"An Open-Label Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2025-08-01","conditions":"Relapsing Polychondritis","enrollment":20},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT03153319","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","startDate":"2017-06-05","conditions":"Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI","enrollment":14},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT01382160","phase":"PHASE4","title":"Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2011-01","conditions":"Rheumatoid Arthritis","enrollment":69},{"nctId":"NCT01895764","phase":"PHASE4","title":"Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2013-03-20","conditions":"Ankylosing Spondylitis","enrollment":110},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT02632175","phase":"PHASE3","title":"Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-11-26","conditions":"Ulcerative Colitis","enrollment":59},{"nctId":"NCT07208539","phase":"PHASE2","title":"AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-10-10","conditions":"Pancreatic Cancer","enrollment":77},{"nctId":"NCT03104400","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-04-27","conditions":"Psoriatic Arthritis","enrollment":1705},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06729463","phase":"NA","title":"IKBKB Gene Polymorphism (Single Nucleotide Polymorphism) (SNP) in Psoriatic and Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"South Valley University","startDate":"2024-12-01","conditions":"Psoriasis, Psoriatic Arthritis","enrollment":50},{"nctId":"NCT03316781","phase":"PHASE3","title":"Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2017-10-27","conditions":"Plaque Psoriasis","enrollment":262},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT06640517","phase":"PHASE3","title":"Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biocad","startDate":"2024-08-08","conditions":"Plaque Psoriasis","enrollment":140},{"nctId":"NCT05928039","phase":"PHASE4","title":"PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease","status":"RECRUITING","sponsor":"University of Calgary","startDate":"2023-10-25","conditions":"Crohn Disease","enrollment":297},{"nctId":"NCT07013838","phase":"PHASE4","title":"The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis","status":"NOT_YET_RECRUITING","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2025-06-15","conditions":"Takayasu Arteritis (TAK)","enrollment":50},{"nctId":"NCT05414201","phase":"PHASE4","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2022-07-07","conditions":"Non-infectious Intermediate Posterior- or Pan-uveitis","enrollment":87},{"nctId":"NCT03261102","phase":"NA","title":"TDM Guided Early Optimization of ADAL in Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"waqqas.afif","startDate":"2017-01-17","conditions":"Crohn Disease, Drug Monitoring, Inflammatory Bowel Diseases","enrollment":200},{"nctId":"NCT06310837","phase":"NA","title":"Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-03-27","conditions":"Uveitis","enrollment":128},{"nctId":"NCT03828019","phase":"PHASE3","title":"Adalimumab vs. Conventional Immunosuppression for Uveitis Trial","status":"COMPLETED","sponsor":"JHSPH Center for Clinical Trials","startDate":"2019-09-16","conditions":"Uveitis","enrollment":227},{"nctId":"NCT03816397","phase":"PHASE4","title":"Adalimumab in JIA-associated Uveitis Stopping Trial","status":"COMPLETED","sponsor":"Nisha Acharya","startDate":"2020-03-15","conditions":"Uveitis, JIA","enrollment":87},{"nctId":"NCT03464136","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2018-03-29","conditions":"Crohn Disease","enrollment":386},{"nctId":"NCT03906136","phase":"PHASE3","title":"AScalate: Treat-to-target in Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-04","conditions":"Axial Spondyloarthritis","enrollment":304},{"nctId":"NCT04088409","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 2 Years to Less Than 18 Years Old With Active JIA-Associated Uveitis or Chronic Anterior Antinuclear Antibody-Positive Uveitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2019-10-16","conditions":"Uveitis","enrollment":30},{"nctId":"NCT03505008","phase":"PHASE4","title":"Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan","status":"COMPLETED","sponsor":"Keio University","startDate":"2018-04-18","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT06849908","phase":"PHASE2","title":"Baricitinib in the Treatment of Intestinal Behçet's Syndrome","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-11-08","conditions":"Behcet Syndrome, Intestinal Type","enrollment":56},{"nctId":"NCT02706704","phase":"PHASE2","title":"Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis","status":"RECRUITING","sponsor":"American University of Beirut Medical Center","startDate":"2016-02","conditions":"Uveitis, Non-Infectious Uveitis","enrollment":32},{"nctId":"NCT04909801","phase":"PHASE3","title":"A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2021-09-15","conditions":"Rheumatoid Arthritis","enrollment":338},{"nctId":"NCT02852694","phase":"PHASE4","title":"Reduce Risk for Crohn's Disease Patients","status":"COMPLETED","sponsor":"PIBD-Net","startDate":"2017-02-28","conditions":"Crohn's Disease","enrollment":192},{"nctId":"NCT04200547","phase":"NA","title":"Interest of the Dosage of Adalimumab Serum Levels in Crohn's Disease Patients for Prevention of Postoperative Recurrence","status":"TERMINATED","sponsor":"University Hospital, Montpellier","startDate":"2020-01-29","conditions":"Crohn Disease","enrollment":42},{"nctId":"NCT05180526","phase":"PHASE4","title":"Assessment of Safety , Clinical Efficacy with QLETLI in Non-infectious Uveitis (UV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2021-12-27","conditions":"Uveitis","enrollment":60},{"nctId":"NCT06742606","phase":"EARLY_PHASE1","title":"Efficacy of Biological Therapy in Pediatric Inflammatory Bowel Disease","status":"NOT_YET_RECRUITING","sponsor":"Ain Shams University","startDate":"2025-01-15","conditions":"Effect of Drug","enrollment":40},{"nctId":"NCT05169593","phase":"PHASE4","title":"Prevention of Postoperative Endoscopic Recurrence with Endoscopy-driven Versus Systematic Biological Therapy","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2022-09-08","conditions":"Crohn Disease","enrollment":292},{"nctId":"NCT06062875","phase":"PHASE2","title":"Effects of TNF Blockade on Human BPH/LUTS","status":"RECRUITING","sponsor":"Endeavor Health","startDate":"2024-01-24","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":70},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT04009668","phase":"PHASE2","title":"Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2019-10-02","conditions":"FSGS, MCD, Focal Segmental Glomerulosclerosis","enrollment":7},{"nctId":"NCT05637515","phase":"PHASE3","title":"Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity","status":"COMPLETED","sponsor":"Biocon Biologics Inc.","startDate":"2022-11-21","conditions":"Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis","enrollment":374},{"nctId":"NCT06498089","phase":"PHASE4","title":"A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-06-28","conditions":"Takayasu Arteritis","enrollment":124},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT02450513","phase":"","title":"Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-03","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05590416","phase":"","title":"A Study of Adalimumab in Acute Vogt-Koyanagi-Harada Disease","status":"RECRUITING","sponsor":"Tianjin Medical University","startDate":"2021-06-01","conditions":"Vogt-Koyanagi-Harada Disease, Adalimumab","enrollment":15},{"nctId":"NCT04230213","phase":"PHASE3","title":"A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-01-13","conditions":"Rheumatoid Arthritis","enrollment":455},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT02660580","phase":"PHASE3","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Fresenius Kabi SwissBioSim GmbH","startDate":"2016-02-16","conditions":"Psoriasis, Plaque Type Psoriasis, Moderate to Severe Plaque Psoriasis","enrollment":443},{"nctId":"NCT06005532","phase":"PHASE3","title":"Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®","status":"UNKNOWN","sponsor":"Mabscale, LLC","startDate":"2023-10-02","conditions":"Plaque Psoriasis","enrollment":494},{"nctId":"NCT03759288","phase":"PHASE2, PHASE3","title":"An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2018-12-07","conditions":"Crohn's Disease, IBD","enrollment":89},{"nctId":"NCT05527444","phase":"PHASE4","title":"The Clinical Efficacy and the Changes of Immune Cells Subsets With Bioagents in Ankylosing Spondylitis Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-03-15","conditions":"Ankylosing Spondylitis","enrollment":100},{"nctId":"NCT04988308","phase":"PHASE2","title":"A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-12","conditions":"Hidradenitis Suppurativa","enrollment":151},{"nctId":"NCT04798755","phase":"PHASE3","title":"Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis","status":"UNKNOWN","sponsor":"Hospital San Carlos, Madrid","startDate":"2022-01-12","conditions":"Uveitis","enrollment":192},{"nctId":"NCT02760407","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease","status":"COMPLETED","sponsor":"R-Pharm International, LLC","startDate":"2016-06-06","conditions":"Rheumatoid Arthritis","enrollment":1648},{"nctId":"NCT04261010","phase":"NA","title":"TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_(TIGERS) Study","status":"COMPLETED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2020-01-14","conditions":"Psoriatic Arthritis","enrollment":36},{"nctId":"NCT03259074","phase":"PHASE3","title":"Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-11-30","conditions":"Ankylosing Spondylitis","enrollment":859},{"nctId":"NCT05151848","phase":"PHASE4","title":"Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis","status":"UNKNOWN","sponsor":"Chinese SLE Treatment And Research Group","startDate":"2022-01-05","conditions":"Takayasu Arteritis","enrollment":100},{"nctId":"NCT05957120","phase":"","title":"Subclinical Impairment of Cardiovascular System in Patients With Psoriasis","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-01-03","conditions":"Psoriasis, Inflammation, Endothelial Dysfunction","enrollment":100},{"nctId":"NCT02764762","phase":"PHASE4","title":"Triple Combination Therapy in High Risk Crohn's Disease (CD)","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-18","conditions":"Crohn Disease","enrollment":55},{"nctId":"NCT05014555","phase":"","title":"Sustained Humoral and Cell-Mediated Immunogenicity of COVID-19 Vaccines in Patients With Inflammatory Bowel Disease","status":"UNKNOWN","sponsor":"GI Alliance","startDate":"2023-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":400},{"nctId":"NCT04183608","phase":"PHASE4","title":"A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2020-01-14","conditions":"Ulcerative Colitis","enrollment":238},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05510063","phase":"PHASE4","title":"Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2022-08-04","conditions":"Plaque Psoriasis","enrollment":371},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT05720221","phase":"","title":"Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients","status":"COMPLETED","sponsor":"Helwan University","startDate":"2021-07-15","conditions":"IBD","enrollment":100},{"nctId":"NCT05683054","phase":"PHASE4","title":"A Non-inferiority Study on Dose Reduction of Adalimumab in Psoriasis Patients Who Are Overtreated","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2020-08-11","conditions":"Psoriasis","enrollment":19},{"nctId":"NCT02147600","phase":"","title":"Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients","status":"COMPLETED","sponsor":"University Hospital, Ghent","startDate":"2014-01-09","conditions":"Psoriasis","enrollment":82},{"nctId":"NCT05626348","phase":"PHASE4","title":"The Clinical Efficacy of Immunomodulators in RA Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-12-22","conditions":"Arthritis, Rheumatoid","enrollment":400},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT05020730","phase":"PHASE2","title":"Trial to Determine the Immunomodulatory Activity of PTM-001 in Patients With Hidradenitis Suppurativa","status":"UNKNOWN","sponsor":"Phoenicis Therapeutics","startDate":"2022-05-05","conditions":"Hidradenitis Suppurativa","enrollment":50},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT04551352","phase":"PHASE1","title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma","enrollment":20},{"nctId":"NCT04132388","phase":"PHASE4","title":"Hidradenitis Suppurativa Patient Experience With Humira Treatment","status":"WITHDRAWN","sponsor":"Wake Forest University Health Sciences","startDate":"2020-08-20","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT04115748","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2019-12-03","conditions":"Psoriatic Arthritis","enrollment":67},{"nctId":"NCT04453137","phase":"PHASE3","title":"Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2020-06-30","conditions":"Plaque Psoriasis","enrollment":567},{"nctId":"NCT02332590","phase":"PHASE3","title":"Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-01-28","conditions":"Rheumatoid Arthritis","enrollment":369},{"nctId":"NCT02714322","phase":"PHASE3","title":"MYL-1401A Efficacy and Safety Comparability Study to Humira®","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2015-06","conditions":"Psoriasis, Arthritis, Psoriatic","enrollment":294},{"nctId":"NCT00730717","phase":"PHASE2","title":"Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum","status":"WITHDRAWN","sponsor":"Wright State University","startDate":"2009-05","conditions":"Pyoderma Gangrenosum","enrollment":""},{"nctId":"NCT01971970","phase":"","title":"Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2013-10","conditions":"Inflammatory Bowel Diseases","enrollment":45},{"nctId":"NCT04588818","phase":"PHASE2","title":"Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2020-02-01","conditions":"Uveitis","enrollment":30},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05153200","phase":"PHASE4","title":"Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01373151","phase":"PHASE2","title":"Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2011-06","conditions":"Rheumatoid Arthritis","enrollment":418},{"nctId":"NCT04171414","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2019-09-09","conditions":"Rheumatoid Arthritis","enrollment":62},{"nctId":"NCT03789292","phase":"PHASE3","title":"A Study to Compare Efficacy and Safety of CT-P17 With Humira in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Celltrion","startDate":"2018-11-26","conditions":"Rheumatoid Arthritis","enrollment":648},{"nctId":"NCT05120687","phase":"","title":"Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2021-10-15","conditions":"Vogt Koyanagi Harada Disease (VKH)","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HUMIRA"],"phase":"phase_3","status":"active","brandName":"Adalimumab Every Week","genericName":"Adalimumab Every Week","companyName":"Innovaderm Research Inc.","companyId":"innovaderm-research-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Adalimumab is a TNF-alpha inhibitor monoclonal antibody that blocks tumor necrosis factor-alpha to reduce inflammation and immune-mediated disease activity. Used for Rheumatoid arthritis, Psoriasis, Crohn's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}